GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (LTS:0I3Q) » Definitions » Profitability Rank

Corcept Therapeutics (LTS:0I3Q) Profitability Rank : 8 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Corcept Therapeutics Profitability Rank?

Corcept Therapeutics has the Profitability Rank of 8. It has a higher profitability and may stay that way.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Corcept Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was 20.09%. As of today, Corcept Therapeutics's Piotroski F-Score is 5.


Competitive Comparison of Corcept Therapeutics's Profitability Rank

For the Biotechnology subindustry, Corcept Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Profitability Rank falls into.



Corcept Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Corcept Therapeutics has the Profitability Rank of 8. It has a higher profitability and may stay that way.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Corcept Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=29.5 / 146.808
=20.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Corcept Therapeutics has an F-score of 5 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Corcept Therapeutics Inc operating margin has been in a 5-year decline. The average rate of decline per year is -8.8%.

4. Consistency of the profitability

5. Predictability Rank


Corcept Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics (LTS:0I3Q) Business Description

Traded in Other Exchanges
Address
149 Commonwealth Drive, Menlo Park, CA, USA, 94025
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Corcept Therapeutics (LTS:0I3Q) Headlines

No Headlines